Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00411580
Status:
COMPLETED
Last Update Posted:
2013-03-29
First Post:
2006-12-13
Brief Title:
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimers Disease AD
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 52-week Multi-center Randomized Double-blind Placebo-controlled Time-lagged Parallel Group Study in Patients With Mild to Moderate Alzheimers Disease AD to Investigate the Safety Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106
Status:
COMPLETED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimers Disease
Patients also had a 2 year follow-up to assess disease progression where no drug was administered
Patients also had a 2 year follow-up to assess disease progression where no drug was administered
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None